Publicaciones en las que colabora con ANTONIO MOLINA CARBALLO (33)

2024

  1. Changes in Cortisol and in Oxidative/Nitrosative Stress Indicators after ADHD Treatment

    Antioxidants, Vol. 13, Núm. 1

2023

  1. Is S100B Involved in Attention-Deficit/Hyperactivity Disorder (ADHD)? Comparisons with Controls and Changes Following a Triple Therapy Containing Methylphenidate, Melatonin and ω-3 PUFAs

    Nutrients, Vol. 15, Núm. 3

  2. Low Doses of Melatonin to Improve Sleep in Children with ADHD: An Open-Label Trial

    Children, Vol. 10, Núm. 7

2021

  1. Current evidence on the role of the gut microbiome in ADHD pathophysiology and therapeutic implications

    Nutrients, Vol. 13, Núm. 1, pp. 1-32

  2. Methylphenidate ameliorates the homeostatic balance between levels of kynurenines in ADHD children

    Psychiatry Research, Vol. 303

2020

  1. Indole Tryptophan Metabolism and Cytokine S100B in Children with Attention-Deficit/Hyperactivity Disorder: Daily Fluctuations, Responses to Methylphenidate, and Interrelationship with Depressive Symptomatology

    Journal of Child and Adolescent Psychopharmacology, Vol. 30, Núm. 3, pp. 177-188

2019

  1. Early monitoring of fatty acid profile in children with attention deficit and/or hyperactivity disorder under treatment with omega-3 polyunsaturated fatty acids

    Minerva Pediatrica, Vol. 71, Núm. 3, pp. 313-325

2018

  1. Clinical Considerations Derived From the Administration of Melatonin to Children With Sleep Disorders

    Pediatric Neurology, Vol. 78, pp. 61-69

2017

  1. Analysis of Different Melatonin Secretion Patterns in Children with Sleep Disorders: Melatonin Secretion Patterns in Children

    Journal of Child Neurology, Vol. 32, Núm. 12, pp. 1000-1008

  2. Melatonin treatment reduces oxidative damage and normalizes plasma pro-inflammatory cytokines in patients suffering from charcot-marie-tooth neuropathy: A pilot study in three children

    Molecules, Vol. 22, Núm. 10

2016

  1. Treatments and compositions for attention deficit hyperactivity disorder: A patent review

    Expert Opinion on Therapeutic Patents, Vol. 26, Núm. 7, pp. 799-814

2011

  1. Melatonin treatment counteracts the hyperoxidative status in erythrocytes of patients suffering from Duchenne muscular dystrophy

    Clinical Biochemistry, Vol. 44, Núm. 10-11, pp. 853-858

2010

  1. Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy

    Journal of Pineal Research, Vol. 48, Núm. 3, pp. 282-289

2007

  1. Fluidity and oxidative stress in erythrocytes from very low birth weight infants during their first 7 days of life

    Free Radical Research, Vol. 41, Núm. 9, pp. 1035-1040

  2. Melatonin increases following convulsive seizures may be related to its anticonvulsant properties at physiological concentrations

    Neuropediatrics, Vol. 38, Núm. 3, pp. 122-125

2002

  1. Evaluation of plasma levels of melatonin after midazolam or sodium thiopental anesthesia in children

    Journal of Pineal Research, Vol. 32, Núm. 4, pp. 253-256

2001

  1. Characterization of nocturnal ultradian rhythms of melatonin in children with growth hormone-dependent and independent growth delay

    Journal of Clinical Endocrinology and Metabolism, Vol. 86, Núm. 3, pp. 1181-1187

  2. Effect of propranolol plus exercise on melatonin and growth hormone levels in children with growth delay

    Journal of Pineal Research, Vol. 30, Núm. 2, pp. 75-81

  3. Melatonin and β-endorphin changes in children sensitized to olive and grass pollen after treatment with specific immunotherapy

    International Archives of Allergy and Immunology, Vol. 126, Núm. 1, pp. 91-96

2000

  1. Effect of clonidine on plasma ACTH, cortisol and melatonin in children

    Journal of Pineal Research, Vol. 29, Núm. 1, pp. 48-53